| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
160,760,000 |
| Market
Cap: |
2.43(B) |
| Last
Volume: |
1,059,072 |
Avg
Vol: |
1,649,151 |
| 52
Week Range: |
$14.79 - $33.465 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system disorders. Co. has a portfolio of product including its drug, NUPLAZID (pimavanserin), which has been approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. NUPLAZID is a selective serotonin inverse agonist/antagonist, targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
896,522 |
| Total Buy Value |
$0 |
$0 |
$0 |
$22,707,098 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
81,669 |
96,169 |
367,230 |
457,753 |
| Total Sell Value |
$1,441,921 |
$1,833,627 |
$8,921,846 |
$10,734,640 |
| Total People Sold |
4 |
5 |
6 |
7 |
| Total Sell Transactions |
11 |
19 |
32 |
57 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Walton Alan |
Director |
– • • |
2005-04-20 |
4 |
B |
$6.82 |
$4,000,024 |
D/D |
586,402 |
3,160,238 |
3.92 |
- |
|
| Walton Alan |
Director |
– • • |
2004-06-02 |
4 |
B |
$7.00 |
$1,995,000 |
I/I |
285,000 |
25,979 |
2.25 |
- |
|
| Walton Alan |
Director |
– • • |
2004-06-02 |
4 |
A |
$0.00 |
$0 |
I/I |
2,314,815 |
23,148 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2004-06-02 |
4 |
B |
$7.00 |
$1,050,000 |
I/I |
150,000 |
414,403 |
2.1 |
- |
|
| Gordon Carl L |
Director |
– • – |
2004-06-02 |
4 |
A |
$0.00 |
$0 |
I/I |
886,009 |
354,403 |
|
- |
|
| Hacksell Uli |
Chief Executive Officer |
• • – |
2004-06-02 |
4 |
B |
$7.00 |
$2,100 |
D/D |
300 |
98,216 |
2.73 |
- |
|
| Binder Gordon M |
Director |
– • – |
2004-06-02 |
4 |
A |
$0.00 |
$0 |
I/I |
555,555 |
14,364 |
|
- |
|
| Van Osch Martien |
Director |
– • – |
2004-06-02 |
4 |
B |
$7.00 |
$980,000 |
I/I |
140,000 |
802,391 |
2.1 |
- |
|
| Van Osch Martien |
Director |
– • – |
2004-06-02 |
4 |
A |
$0.00 |
$0 |
I/I |
662,391 |
662,931 |
|
- |
|
| Lytton Michael |
10% Owner |
– – • |
2004-06-02 |
4 |
B |
$7.00 |
$1,995,000 |
D/D |
285,000 |
25,979 |
2.45 |
- |
|
| Lytton Michael |
10% Owner |
– – • |
2004-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,314,815 |
23,148 |
|
- |
|
| Richards Douglas E |
VP of Business DevelopmentOffi |
• – – |
2004-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
35,000 |
|
- |
|
| Hacksell Uli |
Chief Executive OfficerOfficer |
• • – |
2004-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
97,916 |
|
- |
|
| Davis Robert E |
Executive VP of Drug Discovery |
• – – |
2004-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
105,500 |
|
- |
|
| Brann Mark R |
President and Chief Scientific |
• • – |
2004-05-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
417,756 |
|
- |
|
| Brann Mark R |
President and Chief Scientific |
• • – |
2004-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
92,593 |
|
- |
|
| Aasen Thomas H |
Vice President and CFOOfficer |
• – – |
2004-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
50,000 |
|
- |
|
642 Records found
|
|
Page 26 of 26 |
|
|
0.11 (0.72%) 
